Les inhibiteurs des tyrosines kinases (TKI) sont actifs dans divers cancers métastatiques. Ils présentent une bonne tolérance générale avec effets secondaires principalement hépatiques, et dermatologiques. Rarement, ophtalmologiques peuvent survenir : anomalies cils, paupières, troubles de la surface oculaire sécheresse voire érosions cornéennes pouvant aller jusqu’à perforation. Le Régorafenib...

The present studies were undertaken to determine whether the multikinase inhibitors sorafenib/regorafenib cooperated with clinically relevant , phosphatidyl inositol 3 kinase (PI3K)-thymoma viral proto-oncogene (AKT) inhibitors to kill tumor cells. In liver, colorectal, lung, breast, kidney, and brain cancer cells, at clinically achievable doses, sorafenib/regorafenib and the PI3K inhibitor ace...

OBJECTIVES To investigate contrast-enhanced ultrasound (CEUS) with VEGFR2-targeted microbubbles for monitoring therapy effects of regorafenib on experimental colon carcinomas in rats with correlation to dynamic contrast-enhanced MRI (DCE-MRI) and immunohistochemistry. MATERIALS AND METHODS Human colorectal adenocarcinoma xenografts (HT-29) were implanted subcutaneously in n = 21 (n = 11 thera...

Locoregional therapy is the primary treatment for hepatocellular carcinoma (HCC). Sorafenib was approved as a first-line systemic therapy for advanced HCC with associated extrahepatic spread and/or vascular invasion in 2007. However, there are several limitations associated with sorafenib therapy. To overcome these problems, various clinical trials have been conducted to develop additional mole...